Innoviva earnings jolt and share buyback completion

Innoviva (INVA) is back in focus after second quarter results showed higher revenue alongside a swing to a net loss, while the company also completed a previously announced share repurchase program.

At a share price of $21.19, Innoviva’s recent 1-day share price return of 2.12% and 7-day share price return of 3.32% sit against a softer 30-day share price return. The 3-year total shareholder return of 55.35% points to a much stronger longer term picture.

If this earnings move has you thinking about where else growth or risk is being repriced, it could be a useful moment to scan 44 healthcare AI stocks.

The latest quarter left Innoviva with higher revenue, a fresh loss, and a completed buyback that reduced the share count. After this move in the stock, does the current price still tip the risk reward balance toward buyers?

Price-to-earnings of 4.3x for Innoviva: Is it justified?

On a simple earnings yardstick, Innoviva looks inexpensive. The stock closed at $21.19 while trading on a P/E of 4.3x, which screens as undervalued relative to both its own estimated fair level and peers.

The P/E ratio compares the current share price to earnings per share. For a profitable biopharmaceutical company like Innoviva, it gives a quick read on how much investors are paying for each dollar of current earnings. A low P/E can suggest the market is cautious about the durability of those earnings or the outlook for future profitability.

Innoviva stands out here. Its P/E of 4.3x sits well below the estimated fair P/E of 9.6x that our work suggests the market could move toward. It is also described as good value compared with the broader US Pharmaceuticals industry at 16.6x, and relative to a peer average of 15.6x. That is a steep discount to both a fair ratio estimate and the sector, which implies the market price is not giving full weight to current earnings power.

Result: Price-to-earnings of 4.3x (UNDERVALUED)

Alongside the multiple view, the SWS DCF model currently estimates a future cash flow value of $55.33 per share for Innoviva, well ahead of the $21.19 last close. The model projects future cash flows and discounts them back to today using a required return. This helps translate long term expectations into a single fair value estimate.

For a company like Innoviva that has meaningful non cash earnings and forecasts for earnings to decline over the next few years, a DCF framework can help separate short term profit swings from longer term cash generation. The large gap between the DCF output and the market price highlights how much of that possible long term cash profile may not be reflected in the current valuation.

Result: DCF Fair value of $55.33 (UNDERVALUED)

However, Innoviva still faces risks if its biopharmaceutical products underperform or if royalty partnerships, such as the LABA Collaboration Agreement, deliver weaker than expected economics.

Another view on Innoviva using cash flows

The low 4.3x P/E paints Innoviva as inexpensive. The SWS DCF model goes further and arrives at a future cash flow value of $55.33 per share, which sits well above the current $21.19 price and also points to an undervalued stock based on projected cash generation.

Both approaches lean in the same direction on Innoviva, yet each rests on different assumptions around earnings quality and future cash flows. Which one do you place more weight on when thinking about risk versus potential upside?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Innoviva for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals around Innoviva have you on the fence, this is the moment to look at the numbers yourself and move quickly to shape a clear view. To see how the positives stack up against the concerns, start with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Innoviva?

If Innoviva has sharpened your focus, do not stop here. Broader context from other stocks can help you judge whether the risk reward trade off still works for you.

• Spot potential underpriced opportunities before the crowd by scanning companies in the 50 high quality undervalued stocks.
• Prioritise resilience and sleep easier at night by focusing on the 83 resilient stocks with low risk scores.
• Target quality businesses that the market may be overlooking by using the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.